Ken Griffin Cv Rx, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$6.49 - $19.2 $76,582 - $226,560	-11,800 Reduced 84.89%	2,100 $25,000
Q1 2024 May 15, 2024	BUY	$17.99 - $30.49 $62,964 - $106,715	3,500 Added 33.65%	13,900 $253,000
Q4 2023 Feb 14, 2024	SELL	$11.67 - $33.01 $288,249 - $815,347	-24,700 Reduced 70.37%	10,400 $326,000
Q3 2023 Nov 14, 2023	BUY	$13.56 - $18.47 $336,288 - $458,056	24,800 Added 240.78%	35,100 $532,000
Q2 2023 Aug 14, 2023	SELL	$8.57 - $15.44 $53,134 - $95,728	-6,200 Reduced 37.58%	10,300 $159,000
Q1 2023 May 15, 2023	BUY	$7.08 - $19.4 $97,704 - $267,720	13,800 Added 511.11%	16,500 $153,000
Q4 2022 Feb 14, 2023	BUY	$8.94 - $18.35 $24,138 - $49,545	2,700 New	2,700 $49,000

13.5M

49.9K

2.1K

Ticker CVRX
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 20,576,200
Market Cap $179M
Description
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The co...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.